Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

By A. Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortés-Funes, A. Cervantes, G. Freyer and 8 more. Journal of Clinical Oncology, 2000

3,890 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/bcf19a39d4b7f4f824fd5dbf3f547b16743794ff

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “) 5-fluorouracil (5-FU) or the oral FP capecitabine] in various combinations and schedules [2, 3].”
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study (2023, methodology): “The FOLFOX-4 regimen was as previously described.(3) Treatment was supposed to be continued until disease progression (PD) or for 48 weeks (ie, up to 16 cycles of XELOX or 24 cycles of FOLFOX-4), whichever came first.”
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, background): “FOLFOX note 1 [162, 163] + BEV [164] CAPOX + BEV [164, 165] SOX + BEV [157] Fig.”
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011, neutral): “LV • Capecitabine • FOLFOX4 or mFOLFOX6 (CQ-14) Recommended administration period (CQ13) • In principle, the administration period is 6 months.”
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “• FOLFOX (note 1) [57, 58] + Bmab [54] • CapeOX (note 2) + Bmab [59, 60] ▪ SOX + Bmab (note 3) [61] • FOLFIRI (note 4) [62, 63] + Bmab [64, 65] • FOLFOX + Cmab/Pmab [66, 67] • FOLFIRI + Cmab/Pmab [68, 69] • FOLFOXIRI (note 5) [70] ▪ FOLFOXIRI + Bmab [71, 72] • Infusional 5-FU + LV [73, 74] + Bma”
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy (2019, background): “High-grade chronic OIPN occurs in approximately 10% of patients receiving cumulated doses ranging from 510 to 765 mg/m2, while at doses higher than 1000 mg/m2, this condition may be present in almost 50% of patients [45].”
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. (2006, background): “In the present OPTIMOX1 study, median survival time exceeded 20 months among patients with initially inoperable metastatic colorectal cancer with less stringent inclusion criteria than in preceding studies undertaken by the same group.(5,6,20) Of note, the FOLFOX4 arm reproduced the results achieved”
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. (2005, methodology): “Three hundred sixty consecutive, nonseletected patients were entered onto this trial and randomly assigned to receive either the FOLFIRI regimen according to Douillard et al(9) or the FOLFOX4 regimen according to de Gramont et al.(19) Our results showed that no difference in terms of tumor regressio”
8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer (2008, background): “The improved response rates and extension of disease-free period and overall survival has been documented in many studies.(16) With the introduction of VEGF inhibitors, the response rates even further improved and a median survival of stage-IV colorectal cancer of 22 months may be achieved.”
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. (2004, background): “Interesting survival results were obtained with the use of irinotecan or oxaliplatin on metastatic colorectal patients, but a great majority of patients had liver metastasis without peritoneal carcinomatosis.(11,12) Over the past decade, novel therapeutic approaches to peritoneal carcinomatosis have”
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Combination chemotherapy with a fluoropyrimidine plus oxaliplatin or irinotecan (FOLFOX or FOLFIRI) provides higher RRs and better progression-free and (partly) OS times than a fluoropyrimidine (5-FU/leucovorin) alone [I, B] [234, 235].”